TY - JOUR
T1 - Interleukin-27 controls basal pain threshold in physiological and pathological conditions
AU - Sasaguri, Tomoko
AU - Taguchi, Toru
AU - Murata, Yuzo
AU - Kobayashi, Kimiko
AU - Iizasa, Sayaka
AU - Iizasa, Ei’ichi
AU - Tsuda, Makoto
AU - Hirakawa, Naomi
AU - Hara, Hiromitsu
AU - Yoshida, Hiroki
AU - Yasaka, Toshiharu
N1 - Funding Information:
We are grateful to Dr. Y. Miyake, T. Yamashita, Mr. S. Yamamoto, and Mr. R. Tashima for expert technical assistance. We thank Mr. D. Ono and Y. Kitayama for assistance with the experiments. We also thank the Division of Biological Resources and Development, and the Division of Instrumental Analysis, Analytical Research Center for Experimental Sciences, Saga University for providing the required facilities. Financial support from the JSPS_ KAKENHI Grant numbers 26460669 (NH), 24390150 (TY), 15H04766 (TY), and 16K08991 (TS) is gratefully acknowledged.
Publisher Copyright:
© 2018, The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Numerous studies have shown that pain sensation is affected by various immune molecules, such as cytokines, in tissues comprising the sensory pathway. Specifically, it has been shown that interleukin (IL)-17 promotes pain behaviour, but IL-10 suppresses it. IL-27 has been reported to have an anti-inflammatory effect through regulation of T cell differentiation, resulting in reduced IL-17 and induction of IL-10. Thus, we hypothesised that IL-27 would have some regulatory role in pain sensation. Here, we provide evidence that endogenous IL-27 constitutively controls thresholds for thermal and mechanical sensation in physiological and pathological conditions. Mice lacking IL-27 or its receptor WSX-1 spontaneously showed chronic pain-like hypersensitivity. Reconstitution of IL-27 in IL-27-deficient mice reversed thermal and mechanical hypersensitive behaviours. Thus, unlike many other cytokines induced by inflammatory events, IL-27 appears to be constitutively produced and to control pain sensation. Furthermore, mice lacking IL-27/WSX-1 signalling showed additional hypersensitivity when subjected to inflammatory or neuropathic pain models. Our results suggest that the mechanisms underlying hypersensitive behaviours caused by the ablation of IL-27/WSX-1 signalling are different from those underlying established chronic pain models. This novel pain control mechanism mediated by IL-27 might indicate a new mechanism for the chronic pain hypersensitivity.
AB - Numerous studies have shown that pain sensation is affected by various immune molecules, such as cytokines, in tissues comprising the sensory pathway. Specifically, it has been shown that interleukin (IL)-17 promotes pain behaviour, but IL-10 suppresses it. IL-27 has been reported to have an anti-inflammatory effect through regulation of T cell differentiation, resulting in reduced IL-17 and induction of IL-10. Thus, we hypothesised that IL-27 would have some regulatory role in pain sensation. Here, we provide evidence that endogenous IL-27 constitutively controls thresholds for thermal and mechanical sensation in physiological and pathological conditions. Mice lacking IL-27 or its receptor WSX-1 spontaneously showed chronic pain-like hypersensitivity. Reconstitution of IL-27 in IL-27-deficient mice reversed thermal and mechanical hypersensitive behaviours. Thus, unlike many other cytokines induced by inflammatory events, IL-27 appears to be constitutively produced and to control pain sensation. Furthermore, mice lacking IL-27/WSX-1 signalling showed additional hypersensitivity when subjected to inflammatory or neuropathic pain models. Our results suggest that the mechanisms underlying hypersensitive behaviours caused by the ablation of IL-27/WSX-1 signalling are different from those underlying established chronic pain models. This novel pain control mechanism mediated by IL-27 might indicate a new mechanism for the chronic pain hypersensitivity.
UR - http://www.scopus.com/inward/record.url?scp=85050586080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050586080&partnerID=8YFLogxK
U2 - 10.1038/s41598-018-29398-3
DO - 10.1038/s41598-018-29398-3
M3 - Article
C2 - 30038376
AN - SCOPUS:85050586080
SN - 2045-2322
VL - 8
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 11022
ER -